Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.535 USD | -2.69% | +2.33% | -5.25% |
07-10 | Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024 | CI |
07-10 | Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024 |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 298.57 times its estimated earnings per share for the ongoing year.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.25% | 70.21M | - | ||
+8.21% | 100B | A- | ||
+11.97% | 43.89B | A- | ||
-11.76% | 33.24B | B- | ||
+79.34% | 29.36B | A | ||
-12.20% | 16.08B | C | ||
+4.00% | 14.68B | B- | ||
-1.90% | 12.87B | D+ | ||
+178.17% | 10.55B | D | ||
+1.80% | 8.83B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TH Stock
- THTX Stock
- Ratings Theratechnologies Inc.